Prostate Cell News Volume 7.34 | Sep 16 2016

TOP STORY

Ecotropic Viral Integration Site 1, a Novel Oncogene in Prostate Cancer

Researchers investigated the role of the transcriptional regulator Ecotropic Viral Integration site 1 (EVI1), known as an essential modulator of hematopoietic and leukemic stem cell biology, in prostate carcinogenesis. They showed that in healthy prostatic tissue, EVI1 expression is confined to the prostate stem cell compartment located at the basal layer, as identified by the stem cell marker CD44. [Oncogene] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Hypoxia-Independent Gene Expression Signature Associated with Radiosensitization of Prostate Cancer Cell Lines by Histone Deacetylase Inhibition

Scientists investigated gene expression associated with radiosensitisation of normoxic and hypoxic prostate cancer cells by vorinostat. Cells were exposed to vorinostat under normoxia or hypoxia and subjected to gene expression profiling before irradiation and clonogenic survival analysis. [Br J Cancer] Abstract

Overexpression of LLT1 on Prostate Cancer Cells Inhibits NK Cell-Mediated Killing through LLT1-NKRP1A (CD161) Interaction

Investigators found that lectin-like transcript-1 (LLT1) was overexpressed on prostate cancer cell lines and in primary prostate cancer tissues both at the mRNA and protein level. They further showed that LLT1 is retained intracellularly in normal prostate cells with minimal cell surface expression. [Oncotarget] Full Article

Androgen Receptor Differentially Regulates the Proliferation of Prostatic Epithelial Cells In Vitro and In Vivo

The authors report that activation of androgen receptor differentially regulates the proliferation of human prostate epithelial progenitor cells, NHPrE1, in vitro and in vivo. [Oncotarget] Full Article

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer

Investigators discuss N-terminal domain (NTD) inhibition as a novel concept in the field of androgen receptor (AR)-directed therapies for prostate cancer. AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs. [Oncologist] Abstract

A Basal Cell Defect Promotes Budding of Prostatic Intraepithelial Neoplasia

Scientists modeled the invasive budding phenotype of prostatic intraepithelial neoplasia by reducing expression of α6β4 integrin in spheroids formed from two normal human, stable isogenic prostate epithelial cell lines. [J Cell Sci] Abstract

Galeterone and VNPT55 Disrupts Mnk-eIF4E to Inhibit Prostate Cancer Cell Migration and Invasion

Investigators report that galeterone and VNPT55 profoundly inhibit migration and invasion of prostate cancer cells, possibly by downregulating protein expression of several EMT markers via antagonizing the Mnk-eIF4E axis. [FEBS J] Abstract

Contribution of Caudal MüLlerian Duct Mesenchyme to Prostate Development

Researchers demonstrated that the caudal Müllerian duct mesenchyme drives prostate epithelial differentiation and is a key determinant in cell lineage specification between urethral glands and prostate epithelia. [Stem Cells Dev] Abstract

Up-Regulated Expression of LAMP2 and Autophagy Activity During Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells

The authors used LNCaP prostate cancer cells cultured in a serum-free medium for 6 days as a neuroendocrine (NE) model of prostate cancer. Serum deprivation increased the expression of NE markers such as neuron-specific enolase and βIII tubulin and decreased the expression of the androgen receptor protein in LNCaP cells. [PLoS One] Full Article

Targeting Protein Geranylgeranylation Slows Tumor Development in a Murine Model of Prostate Cancer Metastasis

Researchers determined the ability of geranylgeranyl diphosphate synthase inhibition to slow the development of prostate cancer metastasis in a preventative murine model. [Cancer Biol Ther] Abstract

CLINICAL RESEARCH

10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

The comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen testing remains uncertain. Researchers compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate cancer. [N Engl J Med] Abstract | Press Release | Video

Signatures of Prostate-Derived Ets Factor (PDEF) in Cancer

The authors focus on the key findings about the prostate-derived Ets factor’s biological functions, interacting proteins, and its target genes. [Tumour Biol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

£126.5 Million for Oxford Medical Research

The National Institute for Health Research (NIHR) announced that the two Oxford biomedical research centres (BRCs) were among a number throughout England to receive funding for 2017 to 2022 following a competitive bidding process. NIHR BRCs bring together expertise within the NHS and leading research organizations to turn latest discoveries into fundamentally new treatments for patients. [University of Oxford] Press Release

GenomeDx Adds Multiple Leading Cancer Centers to Its Proprietary Genomics Resource Information Database Platform (Decipher GRID)

GenomeDx Biosciences announced that it has expanded access to its Decipher Genomics Resource Information Database (Decipher GRID^®) to a new group of leading cancer centers, allowing them to join the existing Decipher GRID network. [GenomeDx Biosciences] Press Release

NIH Aims to Beef Up Clinical Trial Design as Part of New Data Sharing Rules

Drug companies and academic researchers will have to step up their public reporting of clinical trial results under new federal policies released today. The National Institutes of Health (NIH) also laid out a new plan for submitting clinical trial proposals that aims to beef up the rigor of the studies. [Science Insider] Editorial

Europe Proposes Copyright Reform to Help Scientists Mine Research Papers

The European Commission has announced long-awaited plans to make it easier for researchers to harvest facts and data from research papers — by freeing the computer-aided activity from the shackles of copyright law. [Nature News] Editorial

Reproducibility: Respect Your Cells!

Numerous variables can torpedo attempts to replicate cell experiments, from the batch of serum to the shape of growth plates. But there are ways to ensure reliability. [Nature News] Editorial

Outsourcing, Coming Soon to a Lab Near You

A move toward outsourcing could offer entrepreneurial opportunities for scientists who have expertise that can be applied to doing experimental work for clients. Traditionally, companies started by scientists have sold products coming out of academic research. Scientific outsourcing firms, on the other hand, would sell the research process itself. [Science Careers] Editorial

NEW Stem Cells in Drug Discovery
March 6-7, 2017
Cambridge, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Prostate Cancer Biology (University of Maryland)

Chair of Medical Biology (Masaryk University)

Postdoctoral Fellow(s) – Uterine Fibroids and Prostate Cancer (University of Texas Health Science Center at San Antonio)

Research Intern – Prostate Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Researcher – Prostate Cancer (Oregon Health & Science University)

Professor – Prostate Cancer Research (Boston University School of Medicine)

Postdoctoral Researcher – Tumor Biology (LSU Health Sciences Center)

Research Scientist – Functional Cancer Genomics (Institute of Oncology Research – Bellinzona)

Senior VP and Director Clinical Research – Oncology (Fred Hutchinson Cancer Research Center)

Assistant/Associate Professor – Genitourinary Cancers (The University of Texas MD Anderson Cancer Center)

Associate Editor (PLOS ONE)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.